Q1 Earnings Forecast for Certara Issued By Leerink Partnrs

Certara, Inc. (NASDAQ:CERT - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Certara in a research note issued on Wednesday, February 26th. Leerink Partnrs analyst M. Cherny anticipates that the company will post earnings per share of $0.05 for the quarter. The consensus estimate for Certara's current full-year earnings is $0.28 per share. Leerink Partnrs also issued estimates for Certara's Q2 2025 earnings at $0.07 EPS, Q3 2025 earnings at $0.07 EPS, Q4 2025 earnings at $0.07 EPS and FY2026 earnings at $0.33 EPS.

A number of other equities analysts have also recently issued reports on the stock. William Blair reissued a "market perform" rating on shares of Certara in a report on Thursday, February 27th. Stephens reissued an "overweight" rating and issued a $17.00 target price on shares of Certara in a report on Thursday, February 27th. TD Cowen assumed coverage on shares of Certara in a report on Thursday, February 27th. They issued a "buy" rating and a $16.00 target price on the stock. Finally, Barclays lifted their price target on Certara from $12.00 to $13.00 and gave the company an "equal weight" rating in a report on Friday, February 28th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $15.83.

Certara Stock Performance

NASDAQ CERT traded down $0.29 during trading hours on Monday, reaching $11.62. The company's stock had a trading volume of 1,681,362 shares, compared to its average volume of 974,801. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The business has a 50-day simple moving average of $12.54 and a 200 day simple moving average of $11.63. Certara has a 52 week low of $9.41 and a 52 week high of $19.87. The stock has a market cap of $1.87 billion, a PE ratio of -58.10, a PEG ratio of 9.29 and a beta of 1.60.

Remove Ads

Institutional Investors Weigh In On Certara

A number of hedge funds have recently made changes to their positions in the business. Harbor Capital Advisors Inc. increased its stake in shares of Certara by 18.4% during the third quarter. Harbor Capital Advisors Inc. now owns 20,144 shares of the company's stock valued at $236,000 after acquiring an additional 3,136 shares during the period. Atria Investments Inc increased its stake in shares of Certara by 21.6% during the third quarter. Atria Investments Inc now owns 19,743 shares of the company's stock valued at $231,000 after acquiring an additional 3,501 shares during the period. TimesSquare Capital Management LLC increased its stake in shares of Certara by 3.1% during the third quarter. TimesSquare Capital Management LLC now owns 956,655 shares of the company's stock valued at $11,202,000 after acquiring an additional 29,090 shares during the period. Versor Investments LP acquired a new position in shares of Certara during the third quarter valued at approximately $162,000. Finally, Geneva Capital Management LLC increased its stake in shares of Certara by 0.7% during the third quarter. Geneva Capital Management LLC now owns 5,510,209 shares of the company's stock valued at $64,525,000 after acquiring an additional 37,392 shares during the period. Institutional investors own 73.96% of the company's stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.